UCB SA - BNP Paribas Fortis

pain; which expires with the last to expire licensed patent. The development of lacosamide in epilepsy
is already finalized.
Immunomedics Inc.
In May 2006, Immunomedics, Inc. granted UCB an exclusive worldwide license to develop, market and
sell epratuzumab for the treatment of any human disease except cancer. The agreement remains in force
unless terminated by UCB ceasing to develop or commercialize epratuzumab.
LTS Lohmann Therapie-Systeme AG
In December 1998, LTS Lohmann Therapie-Systeme AG (“LTS”) and Schwarz Pharma entered into a
development and license agreement for rotigotine on a world-wide basis. Initially the territory of Japan
was excluded but was added later. The license under LTS’ share in certain contractual (formulation)
patents for rotigotine is evergreen, while the development part of the agreement expired when Neupro®
/ rotigotine entered the markets. The agreement was assigned by Schwarz Pharma to Schwarz Pharma
Limited/Ireland in December 2002 which, after an asset acquisition of the main rights to rotigotine from
Aderis in 2002, is the Neupro® product rights owner.
Millennium Pharmaceuticals, Inc.
In October 2004, the UCB Group and Millennium Pharmaceuticals, Inc. entered into a collaboration
agreement regarding the research, development and commercialization of new antibody therapeutics
aimed at one validated Millennium Pharmaceuticals, Inc. target.
Wyeth
In July 2000, Celltech R&D Limited (formerly Celltech Chiroscience Limited), an entity which was
acquired by the UCB Group in connection with its acquisition of Celltech in 2004, and Wyeth (formerly
American Home Products) entered into an exclusive collaboration agreement extending a relationship
dating from 1986 to research, develop and commercialise monoclonal antibody conjugates for use in the
therapy and diagnosis of human cancers (including CMC544 and Mylotarg®). The duration of the
agreement is for 40 years from the date when the last collaboration product is first put on sale in any
country.
(c) Manufacturing and Supply Agreements
Cambrex Karlskoga AB
In June 2003, Cambrex Karlskoga AB and Schwarz Pharma entered into a product supply agreement for
the supply of rotigotine API and (S)-5-MAT by Cambrex Karlskoga AB. The initial term of the
agreement is for 15 years after approval date for the product, and will be automatically prolonged for
three years each if not terminated with 24 months prior notice.
Chemtec Leuna GmbH
In December 2005, Chemtec Leuna GmbH and Schwarz Pharma Produktions GmbH (after assignment
of Schwarz Pharma Limited/Ireland) entered into a supply agreement for the supply by Chemtec Leuna
GmbH of lacosamide API and N-Boc-D-Serine, an intermediate of lacosamide. The initial term of the
agreement is ten years after first regulatory approval of lacosamide products and will be prolonged for
consecutive three year periods if not terminated with 24 months prior notice.
Lonza Limited
A11250830/2.25/23 Oct 2009 85